Developers want Hamilton mayor to help fast-track urban-expansion development
A consortium of developers hoping to expand Hamilton’s frozen urban boundary to build thousands of homes on farmland wants ...
Buffalo company tops growth charts, secures major funding
From topping regional growth charts to securing substantial funding, CleanFiber is on a roll. It is one of Business First's ...
The Herald Journal3d
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...
Taiwan News20h
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study ( NCT06617429 ...
Silicon Valley’s Secondary Markets Are Bigger Than Ever
Secondary transactions involving venture-backed startups are on track to hit a new high this year, as companies like OpenAI, ...
manilatimes2d
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
The Phase 1 trial is a randomized, double-blind, placebo-controlled study of single and multiple ascending doses of oral SCY-247 in approximately 100 healthy subjects. The primary endpoint is safety ...
Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...
manilatimes6d
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol "PVLA” as a publicly traded rare disease biopharmaceutical ...
Business Wire4d
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Pha ...
Mitek Systems, Inc. (NASDAQ:MITK) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript December 16, 2024 Mitek Systems, Inc. beats earnings expectations. Reported EPS is $0.33, ...
‘Fast Track Recall’ for holiday devices sold at Walmart, Target
It’s less than two weeks before Christmas and the U.S. Consumer Product Safety Commission has announced a ‘Fast Track Recall‘ ...